JP2023531679A5 - - Google Patents

Info

Publication number
JP2023531679A5
JP2023531679A5 JP2022578970A JP2022578970A JP2023531679A5 JP 2023531679 A5 JP2023531679 A5 JP 2023531679A5 JP 2022578970 A JP2022578970 A JP 2022578970A JP 2022578970 A JP2022578970 A JP 2022578970A JP 2023531679 A5 JP2023531679 A5 JP 2023531679A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
composition according
inhibitor
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022578970A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038445 external-priority patent/WO2021262695A1/en
Publication of JP2023531679A publication Critical patent/JP2023531679A/ja
Publication of JP2023531679A5 publication Critical patent/JP2023531679A5/ja
Pending legal-status Critical Current

Links

JP2022578970A 2020-06-22 2021-06-22 血友病を処置するための方法および組成物 Pending JP2023531679A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042390P 2020-06-22 2020-06-22
US63/042,390 2020-06-22
PCT/US2021/038445 WO2021262695A1 (en) 2020-06-22 2021-06-22 Methods and compositions for treating hemophilia

Publications (2)

Publication Number Publication Date
JP2023531679A JP2023531679A (ja) 2023-07-25
JP2023531679A5 true JP2023531679A5 (cg-RX-API-DMAC7.html) 2024-07-02

Family

ID=76943130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022578970A Pending JP2023531679A (ja) 2020-06-22 2021-06-22 血友病を処置するための方法および組成物

Country Status (12)

Country Link
US (2) US20210393669A1 (cg-RX-API-DMAC7.html)
EP (1) EP4168018A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023531679A (cg-RX-API-DMAC7.html)
KR (1) KR20230027277A (cg-RX-API-DMAC7.html)
CN (3) CN115942940A (cg-RX-API-DMAC7.html)
AU (1) AU2021296786A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026265A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188137A1 (cg-RX-API-DMAC7.html)
IL (1) IL299295A (cg-RX-API-DMAC7.html)
MX (1) MX2023000164A (cg-RX-API-DMAC7.html)
TW (1) TW202216172A (cg-RX-API-DMAC7.html)
WO (1) WO2021262695A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
CA3258531A1 (en) * 2022-06-08 2023-12-14 Genzyme Corporation TREATMENT OF HEMOPHILIA WITH FITUSIRAN
CN118460655B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团(天津)股份有限公司 抑制FXI基因表达的siRNA的制备方法
TW202610665A (zh) * 2024-07-10 2026-03-16 大陸商正大天晴藥業集團股份有限公司 靶向serpinc1的雙鏈核糖核酸

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
IL308717A (en) 2015-12-07 2024-01-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder
JP2020530442A (ja) * 2017-07-10 2020-10-22 ジェンザイム・コーポレーション 血友病を有する対象の出血事象を処置するための方法および組成物

Similar Documents

Publication Publication Date Title
Lai et al. Recombinant interferon‐α in inoperable hepatocellular carcinoma: a randomized controlled trial
JP2018138578A5 (cg-RX-API-DMAC7.html)
Goldsmith et al. Nuclear imaging and clinical features of childhood reflex neurovascular dystrophy: comparison with adults
BR112013010829B1 (pt) Omposição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
JP2022535127A5 (cg-RX-API-DMAC7.html)
JP2018531605A5 (cg-RX-API-DMAC7.html)
Weary et al. Chronic urticaria in association with dermatophytosis: response to the administration of griseofulvin
TW202417035A (zh) 提派肽(tirzepatide)組合物及用途
WO2025195268A1 (zh) 药物组合物在治疗糖尿病周围神经病变上的应用
JP2025500412A5 (cg-RX-API-DMAC7.html)
JP2023544249A5 (cg-RX-API-DMAC7.html)
JP2023020885A5 (cg-RX-API-DMAC7.html)
JP2019504043A (ja) コラーゲン7組成物及びそれを用いる方法
Niraj et al. Precision health optimization program in the management of advanced Parkinson’s disease: a case series
ES3039536T3 (en) Low dose regimen and formulation of a 5-methyl-1,2,4-oxadiazol-3-yl compound
JP2020045332A (ja) 慢性便秘症を治療するための医薬組成物
Chitsaz et al. Comparison of serum oxytetracycline concentration after intravenous and intraosseous administration in dogs
RU2024120372A (ru) Фитусиран для применения в улучшении сообщаемого пациентом исхода у пациентов с гемофилией
BABAMAHMOODI et al. Combination Therapy with Remdisivir and Tocilizumab for COVID-19: Lessons for Futures Studies (Case Report)
RU2053765C1 (ru) Лекарственное средство для профилактики простудных заболеваний у детей
CN112274644A (zh) 一种用于治疗脊柱与骨关节病变并减轻其疼痛的药物
RU2416413C1 (ru) Средство для лечения кровопотери ("спаскровь")
Simpson et al. Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
RU2294772C1 (ru) Способ стимуляции лимфотока коленного сустава у больных с синдромом диабетической стопы
Al-Humairi et al. Fulminant Chromobacterium violaceum Infection With Suspected Septic Arthritis and a Concurrent Dengue Virus Infection: A Case Report